Literature DB >> 9864384

Cyclo-oxygenase-2 in vascular smooth muscle.

D Bishop-Bailey1, T Hla, J A Mitchell.   

Abstract

Two isoforms of cyclo-oxygenase (COX) have been identified; a constitutive isoform (COX-1), found in abundance in platelets and the vascular endothelium, considered important for the roles of prostanoids and a cytokine/mitogen inducible isoform (COX-2), which is thought responsible for the majority of the inflammatory prostanoid production. As a number of COX metabolites regulate vascular smooth muscle cell function and the interaction between the vessel and circulating components, we have discussed the possibility that COX-2 can be induced in, and regulate human arterial or venous smooth muscle cell function. It is now clear that COX-2 can be induced in freshly isolated vessels in culture, which can be further stimulated by addition of pro-inflammatory cytokines. Interestingly, smooth muscle cells derived from saphenous vein can release extremely high levels of prostanoids, and express greater levels of COX-2 protein than internal mammary artery cells. This difference can be accounted for by an arterial cell-specific negative feedback mechanism. In addition to inducing COX-2, certain cytokines regulate smooth muscle function, by regulating cell proliferation, adhesion, and mediator release. The effects of COX-2 activity on these smooth muscle cell responses will be further discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864384     DOI: 10.3892/ijmm.3.1.41

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids.

Authors:  R L Matz; M A de Sotomayor; C Schott; J C Stoclet; R Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Role of COX-2 in the bioactivation of methylenedianiline and in its proliferative effects in vascular smooth muscle cells.

Authors:  Valeria Y Hebert; Brandon Chad Jones; Randy C Mifflin; Tammy R Dugas
Journal:  Cardiovasc Toxicol       Date:  2011-12       Impact factor: 3.231

3.  A role for cyclooxygenase in aging-related changes of beta-adrenoceptor-mediated relaxation in rat aortas.

Authors:  Khong Bee Kang; M A Sharmini Rajanayagam; Andrea van der Zypp; Henryk Majewski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-03       Impact factor: 3.000

Review 4.  Peroxisome proliferator-activated receptors in the cardiovascular system.

Authors:  D Bishop-Bailey
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.

Authors:  Antonia Tabernero; Francis Schneider; Maria Assunta Potenza; Voahanginirina Randriamboavonjy; Sylvette Chasserot; Philippe Wolf; Delia Mitolo-Chieppa; Jean-Claude Stoclet; Ramaroson Andriantsitohaina
Journal:  Intensive Care Med       Date:  2003-01-15       Impact factor: 17.440

6.  Cyclooxygenase involvement in thromboxane-dependent contraction in rat mesenteric resistance arteries.

Authors:  Manlio Bolla; Dong You; Laurent Loufrani; Bernard I Levy; Sylviane Levy-Toledano; Aïda Habib; Daniel Henrion
Journal:  Hypertension       Date:  2004-04-19       Impact factor: 10.190

7.  Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest.

Authors:  Shao-Xiang Weng; Mei-Hua Sui; Shan Chen; Jian-An Wang; Geng Xu; Ji Ma; Jiang Shan; Lu Fang
Journal:  J Zhejiang Univ Sci B       Date:  2009-07       Impact factor: 3.066

8.  Chronic Low-Level Lead Exposure Increases Mesenteric Vascular Reactivity: Role of Cyclooxygenase-2-Derived Prostanoids.

Authors:  Maylla Ronacher Simões; Bruna Fernandes Azevedo; María Jesús Alonso; Mercedes Salaices; Dalton Valentim Vassallo
Journal:  Front Physiol       Date:  2021-01-07       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.